Ozempic-Type Drugs Flagged for Bone Risk
Popular GLP-1 drugs like Ozempic and Wegovy are now linked to a higher risk of osteoporosis and gout, according to new research from the American Academy of Orthopaedic Surgeons. The findings add a new dimension to the health profile of the widely used weight-loss and diabetes medications.
The study, presented at the American Academy of Orthopaedic Surgeons' 2026 annual meeting, was not peer-reviewed and analyzed over 146,000 adults with obesity and Type 2 diabetes. It found that GLP-1 users had about a 30% higher risk of being diagnosed with osteoporosis and a 12% higher risk for gout compared to non-users. The lead author, Dr. John Horneff from the University of Pennsylvania, initiated the research after observing patients on these drugs experiencing serious tendon tears from minor injuries. The study also noted that osteomalacia, a bone-softening condition, while rare, occurred about twice as frequently in those taking GLP-1s. A key factor is that rapid weight loss from any cause, not just these drugs, is a known risk factor for losing bone density. Gout, a painful type of arthritis, can also be triggered by the rapid weight loss that these medications often induce. This isn't the first time GLP-1s' impact on body composition has been noted; significant loss of lean muscle mass is a documented concern. Some studies suggest that 20-35% of total weight lost on these drugs can come from lean tissue, which includes muscle that is vital for supporting the skeleton. However, the science is not settled. Other research has suggested GLP-1s may have a neutral or even protective effect on bones, separate from the effects of weight loss. A separate large-scale analysis found that for patients with Type 2 diabetes, GLP-1 use was actually linked to a lower risk of osteoporosis, complicating the picture. For adults without diabetes taking the drugs solely for weight loss, the same analysis found a 22% higher risk of osteoporosis, suggesting the drug's effect on bone health may differ based on the patient's diabetic status. Researchers emphasize that the new study is observational and doesn't prove the drugs cause these conditions. They recommend that clinicians monitor the bone health of at-risk patients on GLP-1s and that patients focus on diet and exercise to help mitigate any potential bone density loss.
